US FDA to increase misdemeanour prosecutions of pharma executives
This article was originally published in SRA
Executive Summary
Pharmaceutical and medtech executives responsible for assuring compliance with relevant US Food and Drug Administration regulations for products manufactured by their companies may face increased “misdemeanor prosecutions” if they fall short in their designated role.
You may also be interested in...
FDA's Beleaguered Criminal Investigations Unit Now Facing Congressional Scrutiny
After staff complain about becoming the 'Botox police,' a House committee is asking FDA for an update on two previous reports raising issues of management and morale in the Office of Criminal Investigations.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.